Latest news with #DRAGEN
Yahoo
30-05-2025
- Business
- Yahoo
Illumina Introduces a New AI algorithm PromoterAI: Stock to Gain?
Illumina Inc. ILMN recently introduced PromoterAI, a new AI algorithm that accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome. PromoterAI turns data into insights to help researchers accelerate new breakthroughs in diagnosis for rare diseases. It is the latest addition to the company's artificial intelligence ("AI") and software portfolio. Since the announcement on May 29, ILMN's shares declined 0.2%, closing at $84.28 yesterday. The company is breaking new ground with AI technology. In 2019, the Illumina Artificial Intelligence Lab released SpliceAI, a deep learning tool for interpreting noncoding cryptic splice mutations. In 2023, Illumina released PrimateAI-3D, which predicts the pathogenicity of protein-coding variants based on evolutionary conservation and protein structure. PromoterAI is the latest genomic AI algorithmic innovation from Illumina. As a result, we expect the news to boost market sentiment toward ILMN stock. Illumina presently has a market capitalization of $13.34 billion. The company's earnings yield of 5.1% sits comfortably against the industry's -31.7%. It delivered a trailing four-quarter average earnings surprise of 56.4%. Built on state-of-the-art deep learning neural networks, PromoterAI brings unprecedented precision to the interpretation of promoter variants. With PromoterAI applied to whole-genome sequencing ("WGS") data analysis, clinical researchers are empowered to better understand the etiology and drug target potential for rare genetic diseases, common diseases and oncology. PromoterAI will be accessible through Illumina Connected Software, and it is now available as part of DRAGEN secondary analysis. Precomputed PromoterAI scores for all human promoter single-nucleotide variants are freely available for academic and noncommercial research use. Currently, only about 30% of rare disease patients receive an accurate diagnosis from exome sequencing. For many patients, insights may be hidden in what are known as "noncoding regions," which comprise over 98% of the genome and may hold the key to increasing the diagnostic rate. Promoters are key noncoding elements that define where transcription of a gene begins. When promoters are disrupted by genetic mutations, it can have profound consequences for downstream gene expression. The PromoterAI algorithm interprets the genetic sequence of promoters, thus opening the door to precise diagnoses for more patients with rare diseases. Image Source: Zacks Investment Research Per Dimension Market Research's report, AI in the genomics market is estimated to be valued at $1.40 billion in 2025. It is further anticipated to reach $44.93 billion by 2034 at a compound annual growth rate of 47%. Key factors driving the market growth are increasing demand for precision medicine, rising R&D expenditure and growing demand for effective handling tools for managing large data. On Tuesday, Illumina received approval from Japan's Ministry of Health, Labour and Welfare for TruSightTM Oncology (TSO) Comprehensive for Class III/IV Medical Device (Specially Controlled Medical Device). The TSO Comprehensive is the first U.S. FDA-approved, distributable comprehensive genomic profiling in vitro diagnostics (IVD) kit with pan-cancer CDx claims in the United States. Over the past three months, ILMN's shares have risen 0.1% against the industry's 8.5% decline. Illumina currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space include Phibro Animal Health PAHC, Hims & Hers Health HIMS and Prestige Consumer Healthcare PBH. While Phibro Animal Health sports a Zacks Rank #1 (Strong Buy) at present, Hims & Hers Health and Prestige Consumer Health carry a Zacks Rank #2 (Buy) each. You can see the complete list of today's Zacks #1 Rank stocks here. Estimates for Phibro Animal Health's fiscal 2025 earnings per share have jumped 3.6% to $2.01 in the past 30 days. Shares of the company have rallied 37.9% in the past year compared with the industry's 10.1% growth. Its earnings yield of 8.7% compares comfortably with the industry's 0.5%. PAHC's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 30.6%. Hims & Hers Health's shares have surged 172.5% in the past year. Estimates for the company's 2025 earnings per share have jumped 12.5% to 72 cents in the past 30 days. HIMS' earnings beat estimates in two of the trailing four quarters, matched in one and missed in the other, the average surprise being 19.6%. In the last reported quarter, it posted an earnings surprise of 66.7%. Estimates for Prestige Consumer Healthcare's fiscal 2026 earnings per share have increased 1 cent to $4.77 in the past 30 days. Shares of the company have jumped 37.2% in the past year compared with the industry's 10.1% growth. PBH's earnings surpassed estimates in three of the trailing four quarters and matched on one occasion, the average surprise being 2.8%. In the last reported quarter, it delivered an earnings surprise of 1.5%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Illumina, Inc. (ILMN) : Free Stock Analysis Report Prestige Consumer Healthcare Inc. (PBH) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
28-05-2025
- Business
- Yahoo
Illumina's TSO Comprehensive Earns Japan's Approval: Stock to Gain?
Illumina, Inc. ILMN has received approval from Japan's Ministry of Health, Labour and Welfare for TruSightTM Oncology (TSO) Comprehensive for Class III/IV Medical Device (Specially Controlled Medical Device). As genomic insights continue to drive breakthroughs in cancer treatment, the test is designed to make precision oncology more accessible to oncologists and patients. The latest development bolsters the company's oncology portfolio. Illumina also stated that its clinical oncology offerings will be featured at the ASCO Annual Meeting in Chicago, to be held between May 30 and June 3. Since the announcement on May 26, ILMN shares jumped 2.6%, closing at $82.49 yesterday. The company's oncology portfolio offers versatile, scalable solutions — from low to high-throughput instruments — to meet global customer needs. Through pharmaceutical partnerships, it is developing an expanding pipeline of companion diagnostics (CDx), ultimately driving progress in cancer diagnostics and precision medicine. As a result, we expect the news to boost market sentiment toward ILMN stock. Illumina presently has a market capitalization of $12.72 billion. The company's earnings yield of 5.3% sits comfortably against the industry's -31.5% yield. It delivered an earnings beat of 56.4%, on average, in the trailing four quarters. The TSO Comprehensive is the first U.S. FDA-approved, distributable comprehensive genomic profiling in vitro diagnostics (IVD) kit with pan-cancer CDx claims in the United States. A separate CE-marked version was launched in Europe in 2022. Image Source: Zacks Investment Research The single test includes analysis of DNA and RNA variants and interrogates more than 500 genes to profile a patient's solid tumor, helping increase the likelihood of identifying clinically actionable biomarkers that enable targeted therapy selection or clinical trial enrolment. Powered by a streamlined, automated sample-to-report workflow, the CGP test will enable clinicians in Japan to accelerate access to personalized medicine decisions with greater efficiency and precision. Per a Research report, the global precision genomic testing market was valued at $15.49 billion in 2024 and is expected to grow at a compound annual rate of 14.8% through 2030. This market includes a variety of diagnostic tools and techniques to analyze genetic information, leading to more accurate diagnoses, targeted therapies and improved patient outcomes. Rising demand for precision genomic testing is fueled by the need for early disease detection, effective treatment planning and better management of chronic conditions. This month, the company launched the DRAGEN version 4.4 software (v4.4), which includes out-of-the-box oncology applications for clinical research and support for newly announced Illumina multiomics assays. DRAGEN v4.4 enhancements will simplify next-generation sequencing (NGS) analysis for customers while expanding their capabilities. In addition, Illumina, in partnership with Inc., announced the development of the largest commercially available clinical multiomic dataset from 25,000 patients treated with glucagon-like peptide-1 (GLP-1) receptor agonist therapies. The dataset will be made available to the pharma community to advance drug discovery and development. Over the past three months, ILMN shares have fallen 7.1% compared with the industry's 11.6% decline. Illumina currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space include Phibro Animal Health PAHC, Hims & Hers Health HIMS and Prestige Consumer Healthcare PBH. While Phibro Animal Health sports a Zacks Rank #1 (Strong Buy) at present, Hims & Hers Health and Prestige Consumer Health each carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here. Estimates for Phibro Animal Health's fiscal 2025 earnings per share have jumped 3.6% to $2.01 in the past 30 days. Shares of the company have rallied 37.9% in the past year compared with the industry's 10.1% growth. Its earnings yield of 8.7% compares comfortably with the industry's 0.5% yield. PAHC's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 30.6%. Hims & Hers Health shares have surged 172.5% in the past year. Estimates for the company's 2025 earnings per share have jumped 12.5% to 72 cents in the past 30 days. HIMS' earnings beat estimates twice in the trailing four quarters, matched in one and missed on another occasion, the average surprise being 19.6%. In the last reported quarter, it posted an earnings surprise of 66.7%. Estimates for Prestige Consumer Healthcare'sfiscal 2026 earnings per share have increased 1 cent to $4.77 in the past 30 days. Shares of the company have jumped 37.2% in the past year compared with the industry's 10.1% growth. PBH's earnings surpassed estimates in three of the trailing four quarters and matched on one occasion, the average surprise being 2.8%. In the last reported quarter, it delivered an earnings surprise of 1.5%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Illumina, Inc. (ILMN) : Free Stock Analysis Report Prestige Consumer Healthcare Inc. (PBH) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21-05-2025
- Business
- Yahoo
Illumina Stock to Gain From the Launch of New DRAGEN v4.4 Software
Illumina, Inc. ILMN recently unveiled the DRAGEN version 4.4 software (v4.4), the industry's most comprehensive secondary analysis solution. The latest version includes out-of-the-box oncology applications for clinical research, greater accuracy and support for the company's newly announced multiomics assays. The DRAGEN v4.4 enhancements are expected to simplify NGS analysis for customers while expanding their capabilities. The University Hospital of Tübingen in Germany is among the first adopters of the latest DRAGEN version for their groundbreaking study to evaluate the clinical utility of advanced secondary analysis on whole-genome germline testing. Since the announcement on May 13, ILMN shares jumped 3.3% to close at $82.95 yesterday. Providing labs with ready-to-use analysis applications simplifies oncology biomarker detection and reduces customer complexities. By integrating with Illumina Connected Insights, the applications enable a streamlined workflow for analysis and interpretation across diverse research areas, including genetic diseases, oncology, multiomics, infectious diseases and population genomics. Accordingly, we expect the latest development to boost market sentiment toward ILMN stock. Illumina presently has a market capitalization of $13.13 billion. The company's earnings yield of 5.2% sits comfortably against the industry's -33.3% yield. It delivered an earnings beat of 56.4%, on average, in the trailing four quarters. DRAGEN v4.4 will offer "push-button" analysis for oncology workflows, including the first and only commercially available heme WGS application, Solid WGS DNA Tumor-Normal, and pipelines for molecular residual disease (MRD) and WGS analysis, with more coming soon. It will also support the new and emerging multiomics assays, including Illumina Single Cell 3'RNA Prep and Illumina Protein Prep, and in the future will support the anticipated 5-base solution for methylation analysis and Illumina's spatial technology solution. Image Source: Zacks Investment Research DRAGEN v4.4 marks a 30% increase in SV calling accuracy — the software's biggest leap to date — driven by advancements in the multigenome mapper with pangenome reference. These advances help close the gap in structural variant calling accuracy between short- and long-read sequencing capabilities. DRAGEN v4.4 introduces a personalized pangenome reference capability that delivers a 20% boost in accuracy of single-nucleotide variant and indel calling. Furthermore, DRAGEN v4.4 supports new AWS F2 instance types, enabling faster turnaround times and improved scalability in the cloud. Per a Grand View Research report, the global NGS data analysis market was valued at $999.4 million in 2024 and is expected to grow at a compound annual rate of 23.1% by 2030. The rising use of sequencing platforms in clinical diagnosis, due to reduced installation costs, is expected to fuel the market's growth. This month, Illumina, in collaboration with Inc., announced the development of the largest commercially available clinical multiomic dataset from 25,000 patients treated with glucagon-like peptide-1 (GLP-1) receptor agonist therapies. The dataset will be made available to the pharma community to advance drug discovery and development. Over the past three months, ILMN shares have fallen 12% against the industry's 12.8% growth. Illumina currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space include Hims & Hers Health HIMS, Phibro Animal Health PAHC and Prestige Consumer Healthcare PBH. Each of these carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Estimates for Hims & Hers Health's 2025 earnings per share have jumped 21.2% to 63 cents in the past 30 days. Shares of the company have surged 255% in the past year compared with the industry's 21.2% growth. Its earnings yield of 1.1% compares comfortably with the industry's -9.7% yield. HIMS' earnings surpassed estimates in two of the trailing four quarters, matched in one and missed on another occasion, the average surprise being 19.6%. Phibro Animal Health shares have rallied 31.3% in the past year. Estimates for the company's fiscal 2025 earnings per share have jumped 3.6% to $2.01 in the past 30 days. PAHC's earnings beat estimates in each of the trailing four quarters, the average surprise being 30.6%. In the last reported quarter, it posted an earnings surprise of 21.2%. Estimates for Prestige Consumer Healthcare'sfiscal 2026 earnings per share have increased 1 cent to $4.77 in the past 30 days. Shares of the company have jumped 36.8% in the past year compared to the industry's 10.8% growth. PBH's earnings surpassed estimates in three of the trailing four quarters and matched on one occasion, the average surprise being 2.8%. In the last reported quarter, it delivered an earnings surprise of 1.5%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Illumina, Inc. (ILMN) : Free Stock Analysis Report Prestige Consumer Healthcare Inc. (PBH) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19-03-2025
- Business
- Yahoo
Alliance for Genomic Discovery completes 250,000 whole genomes to accelerate drug discovery
Creates one of the largest, most comprehensive clinical genomic datasets of its kind; multiomic data to be added in next phase of program AGD members are using the population-level insights to uncover novel drug targets SAN DIEGO, March 19, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) and Nashville Biosciences, LLC (NashBio), a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt University Medical Center (VUMC), today announced that 250,000 whole genomes have been sequenced for the Alliance for Genomic Discovery (AGD) initiative. Insights from the AGD database are being leveraged to accelerate drug target discovery, therapeutic research and clinical development. "AGD is delivering on its promise of unlocking new discoveries, and we're eager to build on this success with the addition of multiomic measurements to drive advances in therapeutic development," said Todd Christian, senior vice president of services, arrays, and genomic access at Illumina. "The rapid achievement of this major milestone demonstrates the value of our strategic collaborations across the ecosystem to advance unprecedented progress in biologic and therapeutic discovery." An unparalleled R&D resource The resulting AGD dataset is being made available to the alliance's eight biopharma members using Illumina Connected Analytics as a shared research tool and data platform. De-identified DNA samples were provided by NashBio from VUMC's BioVU® biobank, and sequenced by deCODE genetics, a subsidiary of Amgen, using Illumina's complete, end-to-end sequencing workflow including the DRAGEN analysis pipeline, and integrated with de-identified longitudinal clinical phenotype data derived from VUMC's electronic health record data. "The AGD dataset is unique for its diversity and depth and has already proven its value by empowering us to make important discoveries we would not have made without it," said Kári Stefánsson, CEO of deCODE genetics. A study published in Nature in 2024 indicates that drugs in development with a genetic basis are 2.6 times more likely to succeed than those without. This supports the significant impact of genetic evidence in the field of drug discovery. The data generated through AGD will provide a dynamic research platform for years to come and has already yielded initial novel target discoveries and validations by biopharma company members across autoimmune, liver fibrotic, and metabolic diseases. The diversity of data types, demographics, ancestries, and diseases represented in the dataset makes it a valuable resource for life sciences exploration. The next phase of the Alliance for Genomic Discovery will double down on multiomics In the next phase of AGD, its members plan to further expand the breadth, depth, and diversity of the dataset by adding multiomic layers. "We have received extensive AGD member and broader customer interest," said Leeland Ekstrom, PhD, chief executive officer of NashBio. "Based on this extensive market interest, we're exploring proteomics and other omics modalities to further elucidate the underlying mechanisms of disease and enable discovery of promising targets for pharmacological intervention. The whole genomes of 'AGD 1.0' are only the start." As Illumina expands its portfolio of multiomic capabilities, the Alliance for Genomic Discovery anticipates that it will use these technologies to further enrich the dataset and drive deeper biological insights. Illumina recently unveiled a road map of innovations that will establish the industry's largest portfolio of omics solutions and sequencing applications, spanning genomics, spatial transcriptomics, single-cell analysis, CRISPR technologies, epigenetics, and data analytics software. AGD began sequencing to develop its clinical genomic database in January 2023, making it one of the fastest large-scale genomics projects to date. Originally, sequencing was projected to complete later in 2025. Similar programs have required three to five years to complete 100,000 whole genomes. The speed of this effort reflects the collaborative impact of AGD and its participating life sciences organizations. About the Alliance for Genomic Discovery Launched in 2022 by Illumina and NashBio, the Alliance for Genomic Discovery is a multiyear endeavor aiming to accelerate development of therapeutics through large-scale genomics and the establishment of a preeminent clinical genomic resource. Member companies AbbVie, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, GSK, Merck, and Novo Nordisk leverage the data resource to identify disease associations and targets for intervention. To develop the dataset, Illumina next-generation sequencing solutions were used to analyze whole-genome data derived from Vanderbilt University Medical Center's BioVU®, an extensive, high-quality biobank of more than 250,000 de-identified human DNA samples and associated longitudinal, structured, and de-identified clinical data. One of the main objectives of the alliance is to help narrow the gap in the diversity of genomic data and ultimately work toward a more equitable representation of ancestries in genetic research. Learn more at Use of forward-looking statements This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in developing and launching new products and services, including modifying and scaling manufacturing operations, and reliance on third-party suppliers for critical components; (ii) our ability to manufacture robust instrumentation and consumables; and (iii) the acceptance by customers of our newly launched products, which may or may not meet our and their expectations, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter. About Illumina Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube. About NashBio Nashville Biosciences LLC (NashBio), a wholly owned, for-profit subsidiary of Vanderbilt University Medical Center (VUMC), was created to make complex healthcare data easy to use for a wide range of life science research and development applications. Leveraging Vanderbilt University innovation, NashBio harnesses extensive real-world genomics and other longitudinal multi-modal datasets, along with powerful bioinformatics tools, to build and deliver a wide range of data products and services. NashBio works with clients in biotech, pharma, diagnostics, medical devices, and other life sciences domains to support their most critical use cases. We believe smarter data enables better outcomes for our clients and ultimately for patients. For more information, please visit connect with us on LinkedIn or follow us on X at @NashvilleBio. Contacts Investors:Salli Schwartz858-291-6421IR@ Media:Christine DouglassPR@ View original content to download multimedia: SOURCE Illumina, Inc. Sign in to access your portfolio
